ENHERTU Showed Statistically Significant Improvement in IDFS vs. T-DM1 in High-Risk Early Breast Cancer After Neoadjuvant ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant an ...

A 55-year-old woman develops triple-negative breast cancer, rectal adenocarcinoma, and HBV reactivation during pembrolizumab ...

The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...

For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU demonstrated a highly ...

Positive topline results from a planned interim analysis of the DESTINY-Breast05 phase 3 trial showed ENHERTU demonstrated a highly statistically ...

For patients undergoing a blood draw, various factors including illness, dehydration and anxiety may hinder phlebotomists ...

The man was hospitalized but has since been discharged, the New Mexico Department of Health announced Wednesday.

To confirm a diagnosis and determine the stage of the disease, your doctor will use a series of tests: Biopsy: This is the ...

The New Mexico Department of Health reported Wednesday a case of human plague in a 77-year-old man from Bernalillo County.

Nearly half of women are not regularly checking their breasts for potential signs of cancer, a poll has suggested.